Physician Views: Evaluating the launch of Novartis Cosentyx for psoriasis

Physician Views: Evaluating the launch of Novartis Cosentyx for psoriasis

Code: FW-20150605 | Published: Jun-2015 | Pages: - | FirstWord
Price :
$695.00
USD

* Required Fields

$695.00

Details






Approved in both the US and EU at the beginning of the year, Novartis first-to-market IL-17 inhibitor Cosentyx could be the most effective psoriasis treatment available, suggest key opinion leaders recently interviewed by FirstWord.


Novartis certainly appears confident in the commercial outlook for Cosentyx, indicating at an investor presentation last week that the monoclonal antibody could generate peak annual sales of between $4 billion and $5 billion (ViewPoints: As dust settles on brodalumab setback, Novartis touts Cosentyx as game-changer in psoriasis).


Currently being assessed in Phase III studies, Eli Lillys competing IL-17 inhibitor ixekizumab will provide a competitive threat at some point in the future, as will a raft of other, earlier development-stage therapies assessed in FirstWords forthcoming report on the psoriasis market.


It remains unclear as to whether a recently announced safety concern for another IL-17 inhibitor - AstraZenecas brodalumab, which may or may not reach the market - will prove beneficial to Cosentyx or will heighten caution towards the class until long-term safety data is available.








With Cosentyx now available for some months, and with the product poised to be one of the biggest new drug approvals of 2015, FirstWord is polling dermatologists with the following questions...


- In your experience with Cosentyx (secukinumab) to date, how would you characterise efficacy?
- In your experience with Cosentyx to date, how would you characterise safety/tolerability?
- Over the next 12 months, how do you expect your usage of Cosentyx to change?
- Have side-effect concerns with another development-stage anti 1L-17 antibody (brodalumab) had/will have any adverse impact on your usage of Cosentyx?
- In 12 months time, in what percentage of patients would you expect to be using Cosentyx as the first-line biologic therapy?



Report Format

Following are different modes of Licenses.

a. Single User License:
This license allows only one person to use the report. This person can use the report on any computer and may take print outs of the report but must take care of not sharing the report (or any information contained therein) with any other individual or people. Unless you purchase a Site License or a Global Site License, a Single User License must be purchased for every single person that wishes to use the report within the same enterprise.

b. Single Site License:
This license allows unlimited users to use the report within one company location, e.g. a regional office. These users can use the report on any computer and may take print outs of the report but must take care of not sharing the report (or any information contained therein) with any other individual or people.

c. Global Site License:
A Global Site License (or Enterprise wide Site License or Global License) is a license granted to original purchaser, who can share a report with other employees and authorized Users of the same organization.

Quick Help

1. How do you deliver the reports?
The delivery of reports is depends on format & mode of license of report(s). Following are different kinds of formats of report(s) and their delivery options :

a. Electronic Format – Through email from Publisher
Report will be sent to your username email address in PDF, Excel, PowerPoint or any other electronic / softcopy format by publisher.
Delivery Time: 12 to 48 hours [depending on time difference or occurrences of national holidays]

b. Hard Copy or Printed Format or CD-Rom – Through Mail or Courier from Publisher
Report will be sent through mail / courier delivery to your shipping address by publisher.
Delivery Time: Less than, few weeks [depending on time difference or occurrences of national holidays]


2. How can I make payment for publications I purchase?
You could be able to make the payment, in following ways:

a. Online Secure Payment through Credit Card Payment : We accept Visa, Master, AMEX Cards & CCAvenue
b. Transfer of fund to our bank account via Bank transfer or Wire transfer
c. Payment via DD or Cheque
d. Paypal


3. Is it safe to use my credit card on MarketinfoResearch?
Your personal information and online tranaction on Marketinfo Research is secure, private, and tamper-proof. All credit card payments are processed through secure and trusted payment gateways.

If you have a more question about our publications please see our FAQs section or contact us now at cs@marketinforesearch.com.

CUSTOMERS WHO VIEWED THIS REPORT ALSO VIEWED

There are no reports matching the selection.

Browse similar reports by category:
Pharmaceuticals & Healthcare
FirstWord

Our Clients